AZN vs NVS
AstraZeneca PLC and Novartis AG, both Healthcare
Novartis AG is the larger company at $288B against $266B. Over the past year NVS returned +19% against +3.4% for AZN. The RyuScore puts NVS ahead, 75 against 62 out of 100.
| Figure | AZN | NVS |
|---|---|---|
| Last close | $171 | $151 |
| Market cap | $266B | $288B |
| 1-year return | +3.4% | +19% |
| 5-year return | +55% | +121% |
| RyuScoresector-relative, 1–10 | 62/100 | 75/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.